Older adults with HIV may safely switch to a simpler two-drug regimen
NCT ID NCT05911360
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This study looked at whether adults aged 50 and older living with HIV could safely switch from a three-drug pill to a simpler two-drug pill (DTG/3TC) while keeping the virus under control. About 200 participants who already had undetectable virus levels made the switch and were followed for 48 weeks. The results showed that the simpler pill worked just as well at maintaining viral suppression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Phoenix, Arizona, 85015, United States
-
GSK Investigational Site
Bakersfield, California, 93301, United States
-
GSK Investigational Site
Palm Springs, California, 92262, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20005, United States
-
GSK Investigational Site
Ft. Pierce, Florida, 34982, United States
-
GSK Investigational Site
Miami, Florida, 33133, United States
-
GSK Investigational Site
West Palm Beach, Florida, 33407, United States
-
GSK Investigational Site
Augusta, Georgia, 30912, United States
-
GSK Investigational Site
Decatur, Georgia, 30033, United States
-
GSK Investigational Site
Macon, Georgia, 31201, United States
-
GSK Investigational Site
Boston, Massachusetts, 02043, United States
-
GSK Investigational Site
Berkley, Michigan, 48072, United States
-
GSK Investigational Site
Detroit, Michigan, 48202, United States
-
GSK Investigational Site
Kansas City, Missouri, 64111, United States
-
GSK Investigational Site
Omaha, Nebraska, 68198, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89106, United States
-
GSK Investigational Site
The Bronx, New York, 10467, United States
-
GSK Investigational Site
Charlotte, North Carolina, 28204, United States
-
GSK Investigational Site
Greensboro, North Carolina, 27401, United States
-
GSK Investigational Site
Wilmington, North Carolina, 28401-7684, United States
-
GSK Investigational Site
Akron, Ohio, 44304, United States
-
GSK Investigational Site
Portland, Oregon, 97239, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
GSK Investigational Site
Austin, Texas, 78705, United States
-
GSK Investigational Site
Innsbruck, 6020, Austria
-
GSK Investigational Site
Vienna, 1100, Austria
-
GSK Investigational Site
Brussels, 1200, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Toronto, Ontario, M5G 2N2, Canada
-
GSK Investigational Site
Montreal, Quebec, H2L 1N9, Canada
-
GSK Investigational Site
Montreal, Quebec, H4A 3J1, Canada
-
GSK Investigational Site
Nice, 6202, France
-
GSK Investigational Site
Orléans, 45100, France
-
GSK Investigational Site
Paris, 75004, France
-
GSK Investigational Site
Freiburg im Breisgau, 79106, Germany
-
GSK Investigational Site
Hanover, 30625, Germany
-
GSK Investigational Site
München, 80336, Germany
-
GSK Investigational Site
Milan, 20142, Italy
-
GSK Investigational Site
Modena, 41100, Italy
-
GSK Investigational Site
Roma, 161, Italy
-
GSK Investigational Site
Torino, 10149, Italy
-
GSK Investigational Site
Mérida, 97070, Mexico
-
GSK Investigational Site
Monterrey, 64460, Mexico
-
GSK Investigational Site
Amsterdam, 1105 AZ, Netherlands
-
GSK Investigational Site
Rotterdam, 3079 DZ, Netherlands
-
GSK Investigational Site
Utrecht, 3584 CX, Netherlands
-
GSK Investigational Site
Porto, 4099-001, Portugal
-
GSK Investigational Site
Porto, 4200-319, Portugal
-
GSK Investigational Site
Vila Nova de Gaia, 4434-502, Portugal
-
GSK Investigational Site
Guadalajara, 19002, Spain
-
GSK Investigational Site
Manresa Barcelona, 08243, Spain
-
GSK Investigational Site
Sabadell Barcelona, 8208, Spain
-
GSK Investigational Site
Zaragoza, 50009, Spain
-
GSK Investigational Site
Liverpool, L7 8XP, United Kingdom
-
GSK Investigational Site
London, SE1 9RT, United Kingdom
-
GSK Investigational Site
London, SW7 2AZ, United Kingdom
Conditions
Explore the condition pages connected to this study.